Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 4/20 | 0.44 |
| ▸ | FNTB | P49356 | 4/20 | 0.44 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
| ▸ | GNPAT | O15228 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9828632 | 1.00 | NOD1 (0.50) | NOD1HDAC2FNTAFNTBSLC6A5 | |
| SCHEMBL4951961 | 0.90 | NOD1 (0.50) | NOD1HDAC2FNTAFNTBSLC6A5 | |
| SCHEMBL4955334 | 0.87 | NOD1 (0.55) | NOD1HDAC2FNTAFNTBSLC6A5 | |
| SCHEMBL4952063 | 0.86 | HDAC2 (0.43) | NOD1HDAC2FNTAFNTBPGGT1B | |
| SCHEMBL4956223 | 0.85 | HDAC2 (0.42) | NOD1HDAC2FNTAFNTBPGGT1B | |
| SCHEMBL302152 | 0.85 | FNTA (0.58) | NOD1HDAC2FNTAFNTBPGGT1B | |
| SCHEMBL302151 | 0.85 | FNTA (0.58) | NOD1HDAC2FNTAFNTBPGGT1B | |
| SCHEMBL19506439 | 0.83 | HDAC2 (0.41) | NOD1HDAC2FNTAFNTBPGGT1B | |
| SCHEMBL7636751 | 0.83 | FNTA (0.56) | NOD1HDAC2FNTAFNTBPGGT1B | |
| SCHEMBL7636762 | 0.83 | FNTA (0.56) | NOD1HDAC2FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465471-B2 | Palatability of aquaculture feed | NOVUS INTERNATIONAL, INC. (US) | 2008-12-16 | — | — | US | disclosed |
| WO-2007147155-A1 | POLYOL ESTER COMPOUNDS | NOVUS INTERNATIONAL INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070292485-A1 | POLYOL ESTER COMPOUNDS | NOVUS INTERNATIONAL INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20050215623-A1 | Palatability of aquaculture feed | NOVUS INTERNATIONAL, INC. (US) | 2005-09-29 | — | — | US | disclosed |
| EP-1531672-A2 | ANTIMICROBIAL COMPOSITIONS | Novus International, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20040175434-A1 | Antimicrobial compositions | NOVUS INTERNATIONAL, INC. | 2004-09-09 | — | — | US | disclosed |
| WO-2004019683-A2 | ANTIMICROBIAL COMPOSITIONS | NOVUS INTERNATIONAL, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
| EP-0226304-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1991-08-28 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0226304-A1 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1987-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070292485-A1 | POLYOL ESTER COMPOUNDS | PNLIP, ELOVL1, ELOVL5 | NOD1 3692/4885HDAC2 708/4885FNTA 170/4885 |
| US-20050215623-A1 | Palatability of aquaculture feed | TAS2R3, TAS2R1, TAS2R20 | NOD1 3233/4885HDAC2 1949/4885FNTA 3974/4885 |
| US-20040175434-A1 | Antimicrobial compositions | MRPL21, FPR1, ARG1 | NOD1 10/4885HDAC2 2217/4885FNTA 1959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.